BRIEF

on Bausch Health Companies Inc. (NASDAQ:BHC)

Bausch Health Announces Expanded Public Drug Plan Listings for UCERIS® in Canada

Stock price chart of Bausch Health Companies Inc. (EBR:BHC) showing fluctuations.

Bausch Health, Canada Inc., part of Bausch Health Companies Inc., has announced additional public drug plan listings for PrUCERIS® (budesonide) aerosol foam for treating mild to moderate distal ulcerative colitis in adults. The drug is now accessible through public drug plans in Alberta, Prince Edward Island, and Newfoundland and Labrador, as well as federal plans for Indigenous people and Veterans Affairs Canada.

Previously this year, UCERIS was added to drug plans in Ontario, Quebec, Saskatchewan, New Brunswick, and Nova Scotia. Cees Heiman, Senior VP for Europe and Canada at Bausch Health, expressed satisfaction with the rapid inclusion of UCERIS in various public drug plans following negotiations.

UCERIS, available by prescription since September 2023, is the only glucocorticosteroid rectal foam in Canada for inducing remission in distal ulcerative colitis. Studies indicate a significant preference for the foam formulation due to better tolerability and ease of application.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Bausch Health Companies Inc. news